Procurement Summary
Country : USA
Summary : Oligo and Gene Production
Deadline : 21 Aug 2024
Other Information
Notice Type : Tender
TOT Ref.No.: 105238141
Document Ref. No. : 75D30124Q78083
Competition : ICB
Financier : Self Financed
Purchaser Ownership : Public
Tender Value : Refer Document
Purchaser's Detail
Name :Login to see tender_details
Address : Login to see tender_details
Email : Login to see tender_details
Login to see detailsTender Details
Description
The Centers for Disease Control and Prevention (CDC) Influenza Division (ID) is responsible for developing Candidate Vaccine Viruses based on circulating and novel influenza strains. Candidate Vaccine Viruses (CVVs) are reassortant viruses that are used as the starting materials for seasonal and pandemic vaccines. To facilitate the development of the CVVs, CDC uses oligonucleotides and synthetic genes to transcribe the influenza genes to produce the CVVs.
During research on influenza CVVs, many different genes must be constructed, significantly more than is required in CVV production in most cases. The Influenza Division, therefore, requires bulk production of oligonucleotides with relaxed quality standards versus those required for actual CVV production. The sequences will still follow the natural evolution of viruses and, therefore, can still not be predicted.
Active Contract Opportunity Notice ID 75D30124Q78083 Related Notice Department/Ind. Agency HEALTH AND HUMAN SERVICES, DEPARTMENT OF Sub-tier CENTERS FOR DISEASE CONTROL AND PREVENTION Office CDC OFFICE OF ACQUISITION SERVICES
General Information
Contract Opportunity Type: Combined Synopsis/Solicitation (Original)
All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
Original Published Date: Aug 02, 2024 08:13 am EDT
Original Date Offers Due: Aug 21, 2024 05:00 pm EDT
Inactive Policy: 15 days after date offers due
Original Inactive Date: Sep 05, 2024
Initiative: None
Classification
Original Set Aside:
Product Service Code: 6550 - IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS
NAICS Code: 325414 - Biological Product (except Diagnostic) Manufacturing
Place of Performance: Atlanta, GA USA
Documents
Tender Notice
A19_75D301-24-Q-78083.docx